The absolute concentration of tCr also demonstrated a time × treatment interaction ( p = 0.06), where patients receiving ocrelizumab exhibited stable levels over time while those receiving interferon beta-1a experienced an increase after 48 weeks of treatment. There was also a time × treatment interaction for mI ( p = 0.06), arising from a decreasing trend in the ocrelizumab group and increasing trend in the interferon beta-1a group over 96 weeks.
← all excerpts
Magnetic resonance spectroscopy evidence for declining gliosis in MS patients treated with ocrelizumab versus interferon beta-1a.
1
—
—